Cargando…

Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study

OBJECTIVE: To estimate associations between covid-19 vaccination and long covid symptoms in adults with SARS-CoV-2 infection before vaccination. DESIGN: Observational cohort study. SETTING: Community dwelling population, UK. PARTICIPANTS: 28 356 participants in the Office for National Statistics COV...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayoubkhani, Daniel, Bermingham, Charlotte, Pouwels, Koen B, Glickman, Myer, Nafilyan, Vahé, Zaccardi, Francesco, Khunti, Kamlesh, Alwan, Nisreen A, Walker, A Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115603/
https://www.ncbi.nlm.nih.gov/pubmed/35584816
http://dx.doi.org/10.1136/bmj-2021-069676
_version_ 1784709955104800768
author Ayoubkhani, Daniel
Bermingham, Charlotte
Pouwels, Koen B
Glickman, Myer
Nafilyan, Vahé
Zaccardi, Francesco
Khunti, Kamlesh
Alwan, Nisreen A
Walker, A Sarah
author_facet Ayoubkhani, Daniel
Bermingham, Charlotte
Pouwels, Koen B
Glickman, Myer
Nafilyan, Vahé
Zaccardi, Francesco
Khunti, Kamlesh
Alwan, Nisreen A
Walker, A Sarah
author_sort Ayoubkhani, Daniel
collection PubMed
description OBJECTIVE: To estimate associations between covid-19 vaccination and long covid symptoms in adults with SARS-CoV-2 infection before vaccination. DESIGN: Observational cohort study. SETTING: Community dwelling population, UK. PARTICIPANTS: 28 356 participants in the Office for National Statistics COVID-19 Infection Survey aged 18-69 years who received at least one dose of an adenovirus vector or mRNA covid-19 vaccine after testing positive for SARS-CoV-2 infection. MAIN OUTCOME MEASURE: Presence of long covid symptoms at least 12 weeks after infection over the follow-up period 3 February to 5 September 2021. RESULTS: Mean age of participants was 46 years, 55.6% (n=15 760) were women, and 88.7% (n=25 141) were of white ethnicity. Median follow-up was 141 days from first vaccination (among all participants) and 67 days from second vaccination (83.8% of participants). 6729 participants (23.7%) reported long covid symptoms of any severity at least once during follow-up. A first vaccine dose was associated with an initial 12.8% decrease (95% confidence interval −18.6% to −6.6%, P<0.001) in the odds of long covid, with subsequent data compatible with both increases and decreases in the trajectory (0.3% per week, 95% confidence interval −0.6% to 1.2% per week, P=0.51). A second dose was associated with an initial 8.8% decrease (95% confidence interval −14.1% to −3.1%, P=0.003) in the odds of long covid, with a subsequent decrease by 0.8% per week (−1.2% to −0.4% per week, P<0.001). Heterogeneity was not found in associations between vaccination and long covid by sociodemographic characteristics, health status, hospital admission with acute covid-19, vaccine type (adenovirus vector or mRNA), or duration from SARS-CoV-2 infection to vaccination. CONCLUSIONS: The likelihood of long covid symptoms was observed to decrease after covid-19 vaccination and evidence suggested sustained improvement after a second dose, at least over the median follow-up of 67 days. Vaccination may contribute to a reduction in the population health burden of long covid, although longer follow-up is needed.
format Online
Article
Text
id pubmed-9115603
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-91156032022-05-19 Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study Ayoubkhani, Daniel Bermingham, Charlotte Pouwels, Koen B Glickman, Myer Nafilyan, Vahé Zaccardi, Francesco Khunti, Kamlesh Alwan, Nisreen A Walker, A Sarah BMJ Research OBJECTIVE: To estimate associations between covid-19 vaccination and long covid symptoms in adults with SARS-CoV-2 infection before vaccination. DESIGN: Observational cohort study. SETTING: Community dwelling population, UK. PARTICIPANTS: 28 356 participants in the Office for National Statistics COVID-19 Infection Survey aged 18-69 years who received at least one dose of an adenovirus vector or mRNA covid-19 vaccine after testing positive for SARS-CoV-2 infection. MAIN OUTCOME MEASURE: Presence of long covid symptoms at least 12 weeks after infection over the follow-up period 3 February to 5 September 2021. RESULTS: Mean age of participants was 46 years, 55.6% (n=15 760) were women, and 88.7% (n=25 141) were of white ethnicity. Median follow-up was 141 days from first vaccination (among all participants) and 67 days from second vaccination (83.8% of participants). 6729 participants (23.7%) reported long covid symptoms of any severity at least once during follow-up. A first vaccine dose was associated with an initial 12.8% decrease (95% confidence interval −18.6% to −6.6%, P<0.001) in the odds of long covid, with subsequent data compatible with both increases and decreases in the trajectory (0.3% per week, 95% confidence interval −0.6% to 1.2% per week, P=0.51). A second dose was associated with an initial 8.8% decrease (95% confidence interval −14.1% to −3.1%, P=0.003) in the odds of long covid, with a subsequent decrease by 0.8% per week (−1.2% to −0.4% per week, P<0.001). Heterogeneity was not found in associations between vaccination and long covid by sociodemographic characteristics, health status, hospital admission with acute covid-19, vaccine type (adenovirus vector or mRNA), or duration from SARS-CoV-2 infection to vaccination. CONCLUSIONS: The likelihood of long covid symptoms was observed to decrease after covid-19 vaccination and evidence suggested sustained improvement after a second dose, at least over the median follow-up of 67 days. Vaccination may contribute to a reduction in the population health burden of long covid, although longer follow-up is needed. BMJ Publishing Group Ltd. 2022-05-18 /pmc/articles/PMC9115603/ /pubmed/35584816 http://dx.doi.org/10.1136/bmj-2021-069676 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Ayoubkhani, Daniel
Bermingham, Charlotte
Pouwels, Koen B
Glickman, Myer
Nafilyan, Vahé
Zaccardi, Francesco
Khunti, Kamlesh
Alwan, Nisreen A
Walker, A Sarah
Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study
title Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study
title_full Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study
title_fullStr Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study
title_full_unstemmed Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study
title_short Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study
title_sort trajectory of long covid symptoms after covid-19 vaccination: community based cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115603/
https://www.ncbi.nlm.nih.gov/pubmed/35584816
http://dx.doi.org/10.1136/bmj-2021-069676
work_keys_str_mv AT ayoubkhanidaniel trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy
AT berminghamcharlotte trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy
AT pouwelskoenb trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy
AT glickmanmyer trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy
AT nafilyanvahe trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy
AT zaccardifrancesco trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy
AT khuntikamlesh trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy
AT alwannisreena trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy
AT walkerasarah trajectoryoflongcovidsymptomsaftercovid19vaccinationcommunitybasedcohortstudy